baber/WOPTO huggingface dataset:
Patent JP-2001516353-A (JP)
IPC: C07D487/04
Filed: 1998-03-09
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
Patent JP-2001516491-A (JP)
Title: 光学ディスクのための特別注文グラフィック
IPC: G11B23/40
Filed: 1998-03-19
Abstract: (57)【要約】
情報領域（２５）内に高コントラスト画像（２２）を有する光学ディスク（２０）と、そのような画像の形成方法。光学ディスクは、情報領域を含み、該情報領域は、光学ディスクプレーヤーによって読み取り可能なデータを含みうる領域で定義される。データは、情報領域に含まれる。光学的に可視の高コントラスト画像は、情報領域内に形成される。前記方法は、基板（６２）と基板上の感光層（６４）を含む、予め記録されたマスターディスクを提供する工程を含む。感光層の一部を、マスキングプロセス（６７）を用いてマスターディスクの情報領域内において基板の位置まで除去することにより、高コントラスト画像を形成することができる。
Patent JP-2000511271-A (JP)
Title: 扁球型ガス化装置
IPC: F23B99/00
Filed: 1997-05-06
Abstract: (57)【要約】
供給原料物質をガス化する装置及び方法が開示される。装置は、供給原料物質用の入口（１４）及びガス状酸化剤用の入口を有する扁球型ガス化容器（１２）を構成要素とする。燃焼ガス出口（１６）が燃焼ガスの回収を可能にし、灰回収領域がガス化容器内で生成する灰の収集及び除去を可能にする。複数の再循環ベンチュリ管（３５）が、燃焼ガス及び微粒子をガス化領域（３２）の内外で再循環させる。各ベンチュリ管は、ガス状酸化剤入口（１８）を有するプレナム（４０）を包含し、多数のオリフィスがガス化領域内の供給原料床へ向かう高速空気流を発生せしめる。一又は複数のパルス弁と係合する複数の空気砲（５０）が、パルス化した空気流をガス化領域へ供給する。ガス状酸化剤入口（１８、２０、２２）により灰回収領域において灰の炭素含有量制御が可能となる。
Patent JP-2001518848-A (JP)
Title: 回転式摩擦溶接方法と装置
IPC: B23K20/26
Filed: 1998-04-03
Abstract: (57)【要約】
本発明は、溶接されるべきワークピース（２、３）が作業テーブル（７）に配置され、溶接中、クランプ手段（５,６）によって、相互に及び／または作業テーブルにクランプされる回転式摩擦溶接方法に関する。回転溶接手段(１２、１３)は、ワークピース間の接合部に沿って移動するように設けられる一方、溶接中前記ワークピースを加圧する。前記回転溶接手段の回転により前記接合部で生ぜしめられる摩擦熱や、前記回転溶接手段による他のどのような手法によって前記接合部に供給される他の熱をも上回る付加的熱が溶接中及び／またはその前に前記接合部に対し供給される。本発明は、同様に、回転溶接手段の回転により前記接合部で生ぜしめられる摩擦熱や、前記回転溶接手段による他のどのような手法によって前記接合部に供給される他の熱を上回る付加的熱を溶接中及び／またはその前に前記接合部に供給する発熱体（７０）を備えた回転式摩擦溶接装置に関する。
Patent JP-2001507397-A (JP)
Title: 直鎖強化シリコングラフトポリマー
IPC: A61Q1/00
Filed: 1998-04-24
Abstract: (57)【要約】
（ａ）約−１２０℃から約２５℃のＴｇを有するホモポリマーとして重合される少なくとも１種のモノマー、および（ｂ）約２５℃より上から約２５０℃のＴｇを有するホモポリマーとして重合される少なくとも１種のモノマーを含む有機高分子主鎖によって特徴付けられ、約１０００より大きい数平均分子量を有するシリコーンマクロマーを前記主鎖にグラフトさせたシリコーングラフト接着性ポリマーを含有する、パーソナルケア組成物に使用するためのポリマー。
Patent MX-156327-A (MX)
Inventor: ROSINSKI EDWARD JOSEPH
IPC: C10G11/05
Filed: 1981-07-15
Abstract: The octane number and/or the total yield of gasoline obtained by cracking a hydrocarbon chargestock in the presence of a cracking catalyst comprising an active catalyst component and a matrix, is improved when there is added to the cracking catalyst from 0.01 to 1 weight percent, based on the cracking catalyst, of a shape-selective promotor having a silica to alumina mole ratio of above 12 and a constraint index of 1 to 12 as particles thereof.
Patent NZ-195407-A (NZ)
Title: Cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives and pharmaceutical compositions
Inventor: WELCH W MCK
IPC: C07C211/58
Filed: 1980-10-30
Abstract: Novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of serotonin (5-hydroxy-tryptamine), thereby alleviating serotonin abnormalities at central receptor sites. The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthal enamine and its pharmaceutically acceptable acid addition salts.
Patent NZ-200712-A (NZ)
Title: 1-phenylsulphonyl-3-(alkyl or allyl)carbonyloxyureas
Inventor: GRIFFIN D A
IPC: A01N47/34
Filed: 1982-05-24
Abstract: Sulphonyl urea derivatives of formula ArSO2NHCONHY wherein Ar is an optionally substituted phenyl ring and Y is -CO2R1, -CONR2R3, <IMAGE>  wherein R1 to R7 are H, or optionally substituted aliphatic or phenyl radicals. These derivatives are useful as herbicides e.g. for cereals.
Patent NZ-209567-A (NZ)
Title: Milking machine; teat cup pulsations halted when milk flow ceases
Inventor: TADAAKI TANAKA
IPC: A01J5/04
Filed: 1984-09-17
Abstract: A milking apparatus comprises sets of electrodes for detecting milk flows sucked by individual teat cups capped on individual teats, tubes connected to pressure chambers of the respective teat cups, change-over valves operative to supply atmospheric pressure and vacuum periodically and alternately to the tubes, counters for counting times for non-detection of the milk flows by the sets of electrodes, and controller for actuating the change-over valves to supply only atmospheric pressure to the tubes when the counted times of the counters exceed a predetermined time.
Patent NZ-213755-A (NZ)
Title: Antiinflammatory compositions containing piroxicam and pirbuterol, diazepam or trimazosin
Inventor: CRAWFORD T C
IPC: A61K31/54
Filed: 1985-10-09
Abstract: An improved antiinflammatory composition which employs a combination of antiinflammatory piroxicam, or a pharmaceutically acceptable salt thereof, with antidepressant doxepin, bronchodilator pirbuterol, minor tranquillizer diazepam or antihypertensive trimazosin. The invention also concerns the use of a combination of piroxicam with either acetaminophen or pyridoxine for the manufacture of an antiinflammatory medicament having reduced gastrointestinal side effects.
Patent NZ-214055-A (NZ)
Title: Monoclonal antibodies to antigens on non-small cell long carcinoma (nsclc) cells, antigenic peptides, compositions containing the antigens, amd assays for the presence of the antigens
Inventor: HELLSTROM INGEGERD
IPC: A61K/
Filed: 1985-11-04
Abstract: An antigenic composition purified from normal human serum or the culture medium of human non-small cell lung carcinoma cells comprising a non-denatured glycosylated Form I L3 protein, said protein having the following N-terminal amino acid sequence : <IMAGE> a molecular weight of about 94,000 daltons as determined by SDS polyacrylamide gel electrophoresis under reducing conditions, and N-linked glycoside residues in which the terminal residues of the N-linked glycoside residues are sialic acid residues.
Patent NZ-227436-A (NZ)
Title: Cell proliferation inhibiting composition comprising a substituted styrene derivative
Inventor: LEVITZKI ALEXANDER
IPC: C07C255/37
Filed: 1988-12-21
Abstract: There are provided pharmaceutical compositions containing as an active ingredient a compound of the general formula (I): <CHEM> wherein R1 and R2 are each independently CN, CONH2 or COOH or one of R1 ad R2 may be -CSNH2 or, when R1 is CN, R2 can also be the group <CHEM>  R3 is H, CH3 or OH, R4, R5, R6, R7 are each independently H, OH, C1-5 alkyl, C1-5 alkoxy, NH2, CHO, halogen, NO2 or COOH, or R4 and R5 together may represent a group -O-CH2-O-; provided that: (a) when R4 ad R7 are each OH, R3, R5 and R6 are each H and one of R1 and R2 is CN, then the other of R1 and R2 cannot be CONH2; and (b) when R3 and R7 are each H, R5 is OH and R4 and R6 are both H or both C1-5 alkyl, then R1 is CN and R2 is CN or the group <CHEM>  or a pharmaceutically acceptable salt thereof. There are also provided some novel compounds of formula (I) above. The compositions and compounds according to the invention are efficient protein-tyrosine kinase inhibitors and are suitable for the inhibition of proliferative processes in mammalian cells. <IMAGE>
Patent NZ-229578-A (NZ)
Title: Segmented polyether polyurethane-urea
Inventor: REED ANDREW M
IPC: C08G18/48
Filed: 1989-06-15
Abstract: A hydrophilic, segmented polyether polyurethane-urea that exhibits an increase in tensile strength and elongation when wet with water and is capable of forming visually clear films permeable to water vapor is disclosed.
Patent NZ-249548-A (NZ)
Title: Contrast agents comprising gas-containing or gas-generating polymer microparticles in which the polymer is a biodegradable polymer containing methylene diester moieties
Inventor: KLAVENESS JO
IPC: A61K49/22
Filed: 1993-03-05
Abstract: PCT No. PCT/GB93/00470 Sec. 371 Date Jan. 17, 1995 Sec. 102(e) Date Jan. 17, 1995 PCT Filed Mar. 5, 1993 PCT Pub. No. WO93/17718 PCT Pub. Date Sep. 16, 1993The present invention relates to contrast agents comprising gas-containing or gas-generating polymer microparticles and/or microballoons, in which the polymer is a biodegradable polymer containing units of formula -[-(O)m-CO-O-C(R1R2)-O-CO-(O)n-]- . R1 and R2 each represent hydrogen or a carbon-attached monovalent organic group, or together form a carbon-attached divalent organic group, and m and n are each independently zero or one. The contrast agents may be used in diagnostic applications such as ultrasound and MR imaging.
Patent NZ-256449-A (NZ)
Title: Extraction process: 10-deacetylbaccatin iii from yew tree material via aqueous/organic solvent extraction
Inventor: MARGRAFF RODOLPHE
IPC: C07B63/00
Filed: 1993-10-04
Abstract: This invention relates to a process for obtaining 10-deacetylbaccatin III from various parts of yew (Taxus sp.) by extraction with a suitable organic solvent of the aqueous solution obtained after treating the appropriate part of yew with water, followed by selective crystallization of 10-deacetylbaccatin III.
Patent NZ-268567-A (NZ)
Title: Vitamin d derivatives, preparation and pharmaceutical compositions thereof
Inventor: GRUE-SORENSEN GUNNAR
IPC: A61P3/02
Filed: 1994-07-01
Abstract: PCT No. PCT/DK94/00271 Sec. 371 Date Nov. 7, 1995 Sec. 102(e) Date Nov. 7, 1995 PCT Filed Jul. 1, 1994 PCT Pub. No. WO95/02577 PCT Pub. Date Jan. 26, 1995The present invention relates to compounds of formula in which formula X is hydrogen or hydroxy; R1 and R2, which may be the same or different, stand for hydrogen or C1-C4 hydrocarbyl; or R1 and R2, taken together with the carbon atom bearing the group X, can form a C3-C8 carbocyclic ring; Q is a single bond or a C1-C4 hydrocarbylene diradical; R1, R2 and/or Q may be optionally substituted with one or more fluorine atoms; and prodrugs of formula in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo. The compounds show antiinflammatory and immunomodulating effects as well as stong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells.
Patent NZ-335308-A (NZ)
Title: Detergent composition containing a granulated percarbonate
Inventor: HINTON GERALD THOMAS
IPC: C11D17/00
Filed: 1998-01-12
Abstract: A detergent composition comprising sodium metasilicate and sodium tripolyphosphate, 1-15% of a granulated percarbonate, a blend, which encapsulates the percarbonate and does not contain a zeolite or perborate is claimed. The blend comprises a sulphate, carboxymethyl cellulose and nonionic surfactant. The composition is capable of being stored in a water-soluble PVA film packaging for at least nine months
Patent NZ-501866-A (NZ)
Title: Process for producing silica preform by decomposition of an organosilane
Inventor: ROBA GIACOMO STEFANO
IPC: C03B19/10
Filed: 1999-12-16
Abstract: A process for producing a high-purity optical silica preform, comprising (a) vaporization of an organosilicon compound; (b) thermal decomposition of the said organosilicon compound in the vapour state, to give amorphous fused silica particles; (c) deposition of the said amorphous fused silica particles on a support, in which the said organosilicon compound has the formula (I) in which R1,R2 and R3 are each, independently, hydrogen, methyl, ethyl, propyl, isopropyl or a group of formula -Si-(R5R6R7), where R5, R6 and R7 are each, independently, methyl, ethyl, propyl or isopropyl, and R4 is a group of formula -(CH2)m-Si(R5R6R7), where R5, R6 and R7 are as defined above and m is an integer between 0 and 3. Preferably, at least two of the groups R1, R2 and R3 are other than hydrogen. Among these compounds, the ones which are preferred are those which are liquid at room temperature, those with a boiling point of less than about 140 DEG C, preferably between about 70 DEG C and about 140 DEG C, being particularly preferred. Examples of compounds of formula (I) are: (CH3)3-Si-Si-(CH3)3 (hexamethyldisilane) Tris(CH3)3-Si3-Si-H (tris(trimethylsilyl)silane), (CH3)3-Si-CH2-Si-(CH3)3 (bis(trimethylsilyl)methane). Preferably, the compound of formula (I) is hexamethyldisilane.
Patent NZ-505594-A (NZ)
Title: Process for making urethanes derivatives, compositions thereof suitable as inhibitors of enzyme 2,3-epoxysqualene-lanosterol-cyclase
Inventor: MAIER ROLAND
IPC: C07C333/06
Filed: 1998-12-08
Abstract: Urethanes and thio and dithio analogues thereof of the general formula shown, the salts thereof with physiologically acceptable organic and inorganic acids, processes for preparing these compounds and pharmaceutical compositions containing them. The compounds are inhibitors of cholesterol biosynthesis and are suitable for the treatment of hyperlipidaemias, hypercholesterolaemias and atherosclerosis. Wherein; m denotes the numbers 0 or 1, n denotes the numbers 1 or 2, A denotes a single bond, a straight-chained or branched C1-8­alkylene group, a C2-8alkenylene or C2-8alkynylene group, whilst an unsaturated group is not directly bound to the group Y, X denotes an oxygen or sulphur atom, Y denotes an oxygen or sulphur atom, R1 denotes a straight-chained or branched C1-8alkyl group, a C1-6alkenyl group or a C1-6alkynyl group, whilst the multiple bond is isolated from the nitrogen-carbon bond, R2 denotes a hydrogen atom, a straight-chained or branched C1-8alkyl group which may be substituted by a hydroxy or alkoxy group, a C1-6alkenyl group or a C1-6alkynyl group, whilst a hydroxy and alkoxy substituent is not bound in the 1-position and a multiple bond is isolated from the nitrogen­carbon bond, or R1 and R2 together with the nitrogen atom denote a 5- to 7-­membered, saturated heterocyclic ring wherein a methylene group isolated from the nitrogen atom may be replaced by an oxygen or sulphur atom or by an -NH- or -N(alkyl)- group, R3 to R6, which may be identical or different, denote hydrogen atoms or alkyl groups, R7 denotes a straight-chained or branched C1-6alkyl group, a C1-6alkenyl group or a C1-6alkynyl group, whilst the multiple bond is isolated from the nitrogen-carbon bond, R8 denotes a C3-7cycloalkyl group, a phenyl or naphthyl group optionally substituted by one or two halogen atoms or by an alkyl, alkoxy, trifluoromethyl or cyano group or, if A does not denote a single bond, R8 also denotes a hydrogen atom, whilst, unless otherwise stated, alkyl groups contained in the groups mentioned above may contain 1 to 3 carbon atoms and a halogen atom mentioned above may be a fluorine, chlorine or bromine atom.
Patent NZ-508739-A (NZ)
Title: Method for producing cloned tigers by employing inter-species nuclear transplantation technique
Inventor: HWANG WOO-SUK
IPC: C12N5/10
Filed: 2000-06-30
Abstract: Cloned tigers are produced by the method comprising the steps of: (i) Preparing donor somatic cell lines collected from a tiger. (ii) Maturing oocytes collected from ovary of cow or cat in vitro. (iii) Removing cumulus cells surrounding the oocytes, cutting a portion of zona pellucida of the matured oocytes to make a split, and then squeezing out a portion of cytoplasm including the first polar body through the slit to give enucleated recipient oocytes. (iv) A nucleus is transferred to the recipient oocytes by injection of the donor cells to the enucleated recipient oocytes followed by the subsequent electrofusion and activation of the electrofused cells to give embryos. (v) Post activating and culturing embryos in vitro. (vi) The cultured embryos are then transferred into a tiger surrogate mother to produce cloned tigers. Also described is the embryo, which is produced by steps (i) though to (v) using the ear cells of a tiger and the oocytes of Korean cow (Bos taurus coreanae), and the subsequent cloned tiger that is produced.
Patent NZ-509899-A (NZ)
Title: Thiazoline acid derivatives
Inventor: BERGERON RAYMOND J
IPC: C07D277/12
Filed: 1999-08-31
Abstract: Compounds of the formula below, wherein: Z is CH or N; R is H or acyl; R1, R2, R3 and R5 may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms; and R4 is H or alkyl having 1- 4 carbons, and their use in treating pathological conditions responsive to chelation or sequestration of trivalent metal.
Patent NZ-515087-A (NZ)
Title: Tri-aryl acid derivatives as PPAR receptor ligands
Inventor: JAYYOSI ZAID
IPC: A61K31/4402
Filed: 2000-04-28
Abstract: A compound of formula (I), wherein R1-R12, A, B, D, E, Z, Ar I, Ar II and Ar III are as described in the specification. Compounds of this formula are useful in pharmaceutical compositions to be used in the treatment of physiological disorders.
Patent NZ-515094-A (NZ)
Title: Process for forming pile by forcing hollow pile into ground, pouring concrete and then forcing further pile into concrete prior to setting
Inventor: COATS DANIEL HYLTON
IPC: E02D15/04
Filed: 2001-10-29
Abstract: Hollow displacement pile 1 is forced into ground and unset concrete is placed in the hollow space. Pile 1 is then removed and production pile 12 is forced into the unset concrete. The concrete is then allowed to set about and firmly hold pile 12.
Patent NZ-518248-A (NZ)
Title: Process and machine for packaging food products as well as the product obtained
Inventor: O'GALLCOBHAIR LIAM MICHAEL
IPC: A23G9/04
Filed: 2000-09-08
Abstract: A process for packaging a food product such as soft ice-cream, frozen yoghurt or the like in a single-serving package comprises a continuous in-line system in which a pot (9) is formed in a deformable bottom web (2) of plastics material and a lid (12) with dispensing aperture (14) is formed in a top web (4) of plastics material. Food product is filled into the formed pot and the webs are brought together in register with a lid aligned over the mouth of the pot. The lid is sealed to the pot at a sealing station and the aperture in the lid is covered and sealed with a peel-off tab or label (16). To dispense the product for consumption, the tab is removed and the product is extruded by pressing down on the deformable pot to collapse it, forcing the product through the aperture in the lid. To facilitate this, at least a portion of the lid is formed so as to be sufficiently rigid as to provide a bearing surface toward which the pot can be collapsed. In an alternative arrangement, the bearing surface can be provided by a rigid insert placed in the package between the food product and the lid and in this case the lid may be formed from a "filmsy" material.
Patent NZ-518314-A (NZ)
Title: Apparatus and method for treatment of BPPV
Inventor: ANTHONY PHILIP F
IPC: A61B5/11
Filed: 2000-10-25
Abstract: A method and apparatus are disclosed for visually guiding a person's head into a position sequence necessary to allow abnormally positioned crystals to fall out of a posterior membranous semicircular canal to relieve the symptoms of benign paroxysmal positional vertigo. The apparatus includes a fluid suspended, buoyancy neutral inner member (305), which has printed upon it a sequentially numbered series of position bull's eyes, which are connected by a path printed on the inner member (305). The inner member (305) is contained within a transparent, watertight outer housing (302), which has a sighting marking (306) printed upon it. The device is attached to the user's head in a manner such that the outer housing sighting marking (306) and an aligned inner member (305) position bull's eyes can be seen by the user. The inner member (305) has a magnet (390) which keeps it aligned with a magnetic field with the outer housing (302) being movable about the inner member (305).
Patent NZ-521122-A (NZ)
Title: Wireless downhole measurement and control for optimising gas lift well and field performance
Inventor: HIRSCH JOHN MICHELLE
IPC: E21B47/06
Filed: 2001-03-02
Abstract: A method for optimizing the production of a petroleum well is provided. The petroleum well includes a borehole, a piping structure (24) positioned within the borehole, and a tubing string (26) positioned within the borehole for conveying a production fluid. Production of the well is optimized by determining a flow rate of the production fluid within the tubing string (26) and determining a lift-gas injection rate for the gas being injected into the tubing string. The flow rate and injection rate data is communicated along the piping structure of the well to a selected location (44), where the data is collected and analyzed. After analysis of the data, an optimum operating point (152) for the well can be determined
Patent NZ-522542-A (NZ)
Title: Synthetic peptides and uses thereof
Inventor: THOMSON SCOTT ANTHONY
IPC: G16B15/00
Filed: 2001-05-25
Abstract: A synthetic polypeptide is disclosed, which comprises a plurality of different segments from one parent polypeptide, wherein the segments are linked together in a different relationship relative to their linkage in the parent. The differing linkage impedes, abrogates or otherwise alters at least one function associated with the parent polypeptide. Also disclosed are methods for constructing the aforementioned molecules and immunopotentiating compositions and methods for treating and/or preventing a disease or condition.
Patent NZ-525008-A (NZ)
Title: Pyrazole compounds useful as protein kinase inhibitors
Inventor: DAVIES ROBERT
IPC: A61P3/10
Filed: 2001-09-14
Abstract: Pyrazole compositions comprising a pharmaceutically acceptable carrier and a compound of formula (II) are disclosed, wherein: ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, and ring C has an ortho substituent and is optionally substituted in the non-ortho positions; R2 and R2' are optionally taken together with the intervening atoms of form fused ring system, such as an indazole ring; Rx and Ry are optionally taken together with the intervening atoms of form fused ring system, such as a quinazoline ring; and R2, R2', Rx and Ry are as described in the specification. These pyrazole compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.